A recent penalty announcement from the military procurement website has thrust Yuyue Medical into the public spotlight, with its core wholly-owned subsidiary suspended from military purchasing eligibility due to bid rigging. In parallel, multiple regional entities under pharmaceutical firms such as Shanghai Pharma Holding have received similar sanctions in succession. The ongoing penetrating enforcement in the military procurement arena is exposing dual risks embedded in both business operations and group-level governance across the industry.

On August 17, Shanghai Zhongyou Medical High-Tech Co., a wholly-owned subsidiary of Yuyue Medical, was suspended from corresponding military procurement eligibility by the logistics support department's purchasing administration for bid rigging. The penalty adopts a penetrating accountability approach, simultaneously restricting the legal representative, natural-person controlling shareholder, and project authorization representatives, while other enterprises controlled, managed, or represented by these individuals are also barred from participating in related military procurement projects. Shanghai Zhongyou holds significant importance for Yuyue Medical, having been acquired for RMB 827 million in 2016, and it owns well-known disinfection brands such as "Anerdian" and "Jierou," serving as the core pillar of Yuyue's infection control and disinfection business segment. As early as April this year, the military procurement website had issued a notice of proposed penalty regarding the bid rigging incident, with the final penalty materializing four months later. This is not the first time the Yuyue system has encountered issues in military procurement bidding; in June 2025, Yuyue Medical itself was found to have violated regulations after securing pre-qualification for a military procurement project, leading to the cancellation of its pre-qualification status and the rejection of its reconsideration appeal.

Looking across the broader pharmaceutical industry, Yuyue is far from an isolated case. Over the past year, four regional core distribution subsidiaries of Shanghai Pharma Holding have successively crossed military procurement compliance red lines, with subsidiaries in Qingdao, Sichuan, and Dongguan involved in bid rigging, and a Dongying subsidiary submitting falsified bidding materials. The violations span regions including the southwest, Shandong, and south China, with some penalties amounting to full bans on military procurement eligibility. Shanghai Pharmaceuticals recorded receivables of RMB 85.2 billion at the end of 2025, and with prolonged payment cycles in pharmaceutical distribution, cash flow pressure is already pronounced; the loss of military procurement orders further exacerbates operational strain. In June 2026, the Armed Police Force procurement administration disclosed penalty information in a centralized manner, with over 19 enterprises in the Sichuan region suspended from full military procurement eligibility for bid rigging, including subsidiaries of Sinopharm Holding Sichuan and Chongqing Pharmaceutical Group Sichuan among other listed companies. Beyond the direct loss of military procurement market share, the penetrating accountability model severs the pathway for enterprises to evade penalties through affiliated entities. A company's adverse records also spill outward, damaging commercial reputation in other business areas such as public hospital and local government procurement, creating potential risks of order attrition.

The recurrence of bidding violations can no longer be simply attributed to individual employee misconduct, instead reflecting widespread governance deficiencies across large pharmaceutical groups. Medical device and pharmaceutical distribution companies typically rely on regional subsidiaries to penetrate local markets, while group-level management often prioritizes performance metrics, with insufficient process oversight over frontline business operations. Under intense revenue assessment pressure at local operating entities, some practitioners resort to risky behavior in bidding procedures to secure orders. Compliance systems remain confined to headquarter-level documentation, failing to effectively cascade down to grassroots business operations, resulting in repeated outbreaks of similar violations. For companies like Yuyue Medical that have expanded their business footprint through substantial acquisitions, the current subsidiary issue also highlights post-merger compliance integration risks. Core assets acquired at high prices, once integrated into the listed company system, have not seen synchronized upgrades in risk control management, allowing subsidiary violations to directly backfire on the listed parent entity.

The risks facing listed companies carry chain-reaction effects. Successive compliance penalties trigger capital market skepticism regarding the group's overall governance capabilities, with investors worrying that other subordinate enterprises harbor similar hidden risks, leading to pressure on reputation and even valuation. As military procurement oversight tightens and penetrating accountability becomes the norm, pharmaceutical listed companies must rebalance business expansion against risk control, particularly by strengthening full-process bidding supervision over acquired subsidiaries and cross-regional branches, while cementing compliance responsibilities at the grassroots business level. If internal control vulnerabilities are left unaddressed, enterprises will continue losing key procurement markets and invite additional secondary operational risks.

This article was generated with the assistance of AI tools.